Neuropore Therapies (NPT) Inc. is a San Diego, California based biopharmaceutical company developing novel, small molecule therapeutics for the treatment of neurodegenerative disorders. The approaches being taken by Neuropore Therapies target the core pathological processes underlying these disorders, including the intracellular accumulation of neurotoxic misfolded proteins and the associated chronic and maladaptive neuroinflammation that may both initiate and then drive progressive neurodegeneration. By focusing on these underlying processes, Neuropore’s therapeutic candidates will break the vicious cycle of neuroinflammation, protein pathology and neurodegeneration that leads to disease progression. Therapeutic candidates arising from this approach will have broad applications across a wide range of neuroinflammatory degenerative disorders.
Neuropore Therapies is led by a core management team with extensive scientific, drug-development and business experience in both Pharma and Biotechnology companies. The management team and our senior scientists have an established track record of discovering and developing drugs for central nervous system disorders, establishing partnering transactions, and raising funding in both private (venture) and public settings. To complement our internal drug discovery capabilities, NPT utilizes external consultants, advisors and contract research organizations to accelerate development of its drug-discovery pipeline. Neuropore’s scientific and business outreach includes arrangements with pharmaceutical companies such as UCB Pharma, disease-focused foundations including The Michael J. Fox Foundation and academic collaborations with institutions such as the University of California, San Diego, Albert Einstein College of Medicine and The University of Sydney.